Within the SGLT2i cohort, 47% received empagliflozin, 27% received dapagliflozin and 25% received canagliflozin
Maintaining GLP-1 production helps with weight control, particularly for those who face these conditions
With each dose, symptoms are briefly covered, only to reemerge when the medication wears off, reinforcing cycles of dependence, instability, and patient frustration
Sitagliptin: anti-platelet effect in diabetes and healthy volunteers
This sufficiently powered clinical study did not find a beneficial effect of linagliptin versus placebo on albuminuria in patients with T2DM, although exploratory analyses indicated more responders and fewer non-responders in terms of UACR in the linagliptin group
maintain blood sugar stability and enhance metabolic balance